© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
August 05, 2021
Amgen reported a strong increase in biosimilar sales for the year but said competition is forcing down prices and affecting revenues for its originator products, too.
August 04, 2021
August 03, 2021
August 02, 2021
August 01, 2021
Jim Rebello, PharmD, from Magellan Rx Management, discuss how rebates, or lack thereof, have impacted uptake of oncology biosimilars.
July 31st 2021
By Sarfaraz K. Niazi, PhD
Sarfaraz K. Niazi, PhD, discusses the regulatory approval of future messenger RNA (mRNA) vaccines, which will likely face fewer patent issues and are easy to replicate.
July 30th 2021
Here are the top 5 biosimilar articles for the week of July 26, 2021.
July 29th 2021
By Jeff Baldetti, MBA
The approval of Biocon Biologics and Viatris' insulin glargine product as an interchangeable biosimilar will be a test of whether such designations can make a difference in patient access, Jeff Baldetti, MBA, of Cardinal Health explains.
By Tony Hagen
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin.
July 28th 2021
Pfizer reported strong sales for its biosimilars portfolio, but these were eclipsed by the massive success of the company's mRNA vaccine for COVID-19.
BioFactura looks to join the ustekinumab biosimilar race and Cardinal Health provides an interactive tool with state-by-state interchangeable rules.
July 27th 2021
Kashyap B. Patel, MD, says value of care is an important metric, but often people lose sight of what patients have to pay out of pocket, and how this affects them.
July 26th 2021
Biosimilar uptake could be more robust in the United States if the FDA can be convinced that biosimilars are worth the effort, according to Rep Kurt Schrader, D-Oregon.
Concomitant use of immunomodulators and dosage are important variables in the development of antidrug antibodies (ADAs) for patients receiving infliximab for Crohn disease, investigators report.
July 24th 2021
By Alejandro Menchaca, JD
The Biologics Price Competition and Innovation Act (BPCIA) provides a stepwise approach for fact-finding prior to patent litigation, but companies may choose their own path, case examples show.